Tse R, Vavougios G, Hou Y, Mahuran D J
Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
Biochemistry. 1996 Jun 11;35(23):7599-607. doi: 10.1021/bi960246+.
Human beta-hexosaminidases A and B (EC 3.2.1.52) are dimeric lysosomal glycosidases composed of evolutionarily related alpha and/or beta subunits. Both isozymes hydrolyze terminal beta-linked GalNAc or GlcNAc residues from numerous artificial and natural substrates; however, in vivo GM2 ganglioside is a substrate for only the heterodimeric A isozyme. Thus, mutations in either gene encoding its alpha or beta subunits can result in GM2 ganglioside storage and Tay-Sachs or Sandhoff disease, respectively. All glycosyl hydrolases ae believed to have one or more acidic residues in their catalytic site. We demonstrate that incubation of hexosaminidase with a chemical modifier specific for carboxyl side chains produces a time-dependent loss of activity, and that this effect can be blocked by the inclusion of a strong competitive inhibitor in the reaction mix. We hypothesized that the catalytic acid residue(s) should be located in a region of overall homology and be invariant within the aligned deduced primary sequences of the human alpha and beta subunits, as well as hexosaminidases from other species, including bacteria. Such a region is encoded by exons 5-6 of the HEXA and HEXB genes. This region includes beta Arg211 (invariant in 15 sequences), which we have previously shown to be an active residue. This region also contains two invariant and one conserved acidic residues. A fourth acidic residue, Asp alpha 258, beta 290, in exon 7 was also investigated because of its association with the B1 variant of Tay-Sachs disease. Conservative substitutions were made at each candidate residue by in vitro mutagenesis of a beta cDNA, followed by cellular expression. Of these, only the beta Asp196Asn substitution decreased the kcat (350-910-fold) without any noticeable effect on the K(m). Mutagenesis of either beta Asp240 or beta Asp290 to Asn decreased kcat by 10- or 1.4-fold but also raised the K(m) of the enzyme 11- of 3-fold, respectively. The above results strongly suggest that beta Asp196 is a catalytic acid residue in beta-hexosaminidase.
人β-己糖胺酶A和B(EC 3.2.1.52)是由进化相关的α和/或β亚基组成的二聚体溶酶体糖苷酶。两种同工酶都能从多种人工和天然底物中水解末端β-连接的GalNAc或GlcNAc残基;然而,在体内GM2神经节苷脂只是异二聚体A同工酶的底物。因此,编码其α或β亚基的任一基因发生突变,分别可导致GM2神经节苷脂蓄积以及泰-萨克斯病或桑德霍夫病。据信所有糖基水解酶在其催化位点都有一个或多个酸性残基。我们证明,用对羧基侧链特异的化学修饰剂孵育己糖胺酶会导致活性随时间丧失,并且这种效应可通过在反应混合物中加入强竞争性抑制剂来阻断。我们推测催化酸性残基应位于整体同源区域,并且在人α和β亚基以及来自其他物种(包括细菌)的己糖胺酶的比对推导一级序列中是不变的。这样一个区域由HEXA和HEXB基因的外显子5 - 6编码。该区域包括β-精氨酸211(在15个序列中不变),我们之前已证明它是一个活性残基。该区域还包含两个不变和一个保守的酸性残基。由于其与泰-萨克斯病的B1变异体相关,外显子7中的第四个酸性残基天冬氨酸α258、β290也进行了研究。通过对β - cDNA进行体外诱变,然后进行细胞表达,在每个候选残基处进行保守替换。其中,只有β天冬氨酸196替换为天冬酰胺降低了催化常数(350 - 910倍),而对米氏常数没有任何明显影响。将β天冬氨酸240或β天冬氨酸290突变为天冬酰胺分别使催化常数降低10倍或1.4倍,但也分别使酶的米氏常数提高了11倍或增加了3倍。上述结果强烈表明β天冬氨酸196是β-己糖胺酶中的催化酸性残基。